Schizophrenia patients have fewer connections between nerve cells. This is believed to be caused by genetic risk variants leading to an excessive elimination of nerve cell connections by the immune cells of the brain. Researchers at Karolinska Institutet now report in Nature Communications that the levels of protein from the relevant risk gene are elevated in first-episode patients and that inflammation further increases the expression of the risk gene.
In the late-teenage brain, a normal elimination of less desirable connections between nerve cells takes place. The pruning of these connections, so-called synapses, is of great importance for the development of functional neural networks. However, patients with schizophrenia have fewer synapses. A few years ago, researchers at Karolinska Institutet could show in an experimental model that the elimination of synapses is increased in schizophrenia patients and can be linked to the gene coding for complement component 4A (C4A), a protein involved in immune signalling.
Jessica Gracias Lekander, a doctoral student at Karolinska Institutet. Photo: Ada Trepci.
The same team has now developed a method to measure C4A levels in cerebrospinal fluid. In two independent cohorts, they observed elevated C4A levels in first-episode psychosis patients that a few years later would develop schizophrenia.
“After checking for genetic risk variants, we still observed elevated levels of C4A,” says , a doctoral student at the , Karolinska Institutet, and first author of the study.
The pro-inflammatory cytokines IL-1beta and IL-6 have previously been shown to be elevated in schizophrenia, and the researchers performed new experiments in which they could show that these cytokines stimulate the expression of the C4A gene, while patients with high C4A levels also displayed high levels of IL-1beta in cerebrospinal fluid. C4A levels also correlated with markers of synapse density.
Carl Sellgren Majkowitz, researcher at Karolinska Institutet. Photo: Rafael Motta.
“This indicates that the effect we see in the laboratory is also relevant in the brain,” says senior author at the Department of Physiology and Pharmacology, Karolinska Institutet, and Psykiatri Nordväst, Region Stockholm.
The researchers hope that their findings will lead to more effective and personalized treatment strategies and be part of the emerging precision psychiatry.
“Existing treatments are non-personalized and focus on reducing psychotic symptoms in patients that have developed the disorder,” says Carl Sellgren Majkowitz.
The study was primarily funded by the Swedish Research Council, One Mind Foundation/Kaiser Permanente, Erling Persson Foundation, and the Swedish Federal Government under the ALF agreement.
Publication
. Jessica Gracias, Funda Orhan, Elin Hörbeck, Jessica Holmén-Larsson, Neda Khanlarkani, Susmita Malwade, Sravan K. Goparaju, Lilly Schwieler, İlknur Ş. Demirel, Ting Fu, Helena Fatourus-Bergman, Aurimantas Pelanis, Carleton P. Goold, Anneli Goulding, Kristina Annerbrink, Anniella Isgren, Timea Sparding, Martin Schalling, Viviana A. Carcamo Yañez, Jens C. Göpfert, Johanna Nilsson, Ann Brinkmalm, Kaj Blennow, Henrik Zetterberg, Göran Engberg, Fredrik Piehl, Steven D. Sheridan, Roy H. Perlis, Simon Cervenka, Sophie Erhardt, Mikael Landen, Carl M. Sellgren, Nature Communications, online November 3 2022, doi: 10.1038/s41467-022-33797-6
